Compass Therapeutics (CMPX) Reiterated at Market Outperform by Citizens

June 4, 2026 5:22 AM

Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $10.00 price target on Compass Therapeutics (NASDAQ: CMPX).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found